恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 06-16 16:08:14

54.050

+0.000

0.00%

最高55.400	最低53.400	成交量235.40万
今开54.050	昨收54.050	日振幅3.70%
总市值3,587亿	流通市值139.45亿	总股本66.37亿
成交额1.28亿	换手率0.91%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":54.05,"timestamp":1781597294004,"preClose":54.05,"halted":0,"volume":2354037,"delay":0,"changeRate":0,"floatShares":258000000,"shares":6637000000,"eps":1.18,"marketStatus":"未开盘","change":0,"latestTime":"06-16 16:08:14","open":54.05,"high":55.4,"low":53.4,"amount":127584968,"amplitude":0.037003,"askPrice":54.05,"askSize":121000,"bidPrice":54,"bidSize":10200,"shortable":3,"etf":0,"ttmEps":1.38755,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781659800000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":54.05,"dividendRate":0.004287,"openAndCloseTimeList":[[1781573400000,1781582400000],[1781586000000,1781596800000]],"volumeRatio":0.7678511829991407,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":47.35,"timestamp":1781593200000,"preClose":47.88,"halted":0,"volume":50293400,"delay":0,"premium":"-1.54"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2643730703","title":"恒瑞医药：HRS-7525片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2643730703","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643730703?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:03","pubTimestamp":1781600580,"startTime":"0","endTime":"0","summary":"南财智讯6月16日电，恒瑞医药公告，HRS-7525片收到国家药品监督管理局签发的《药物临床试验批准通知书》，审批结论为同意该药单药在晚期实体瘤中开展临床试验；受理号为CXHL2600319、CXHL2600320，申请事项为临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606163773104428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU1655091616.SGD","BK0188","BK0060","BK0183","LU0405327494.USD","LU1064130708.USD","LU1255011170.USD","BK0012","01276","LU1064131003.USD","LU1969619763.USD","LU2543165471.USD","LU2097828557.USD","LU2495084118.USD","LU1997244956.HKD","LU2580892789.USD","LU1580142542.USD","LU2097828714.EUR","600276","LU2097828474.EUR","LU2289578879.USD","LU2097828631.EUR","LU2328871848.SGD","LU0359201885.HKD","LU1146622755.USD","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1023057109.AUD","BK0028","LU0359201612.USD","LU1997245177.USD","LU2148510915.USD","BK0196","LU2580892862.HKD","LU1781817850.SGD","LU2097828805.USD","LU1997245094.SGD","LU1820825898.SGD","BK0239","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1880383366.USD","09996","BK1576","SG9999002562.SGD","01093","HK0000320264.USD","06990","BK1191","LU1960683339.HKD","01530","LU0819121731.USD","LU2097828631.EUR","IE00BZ08YR35.GBP","LU0737861772.HKD","LU0348827113.USD","03329","IE00B0JY6N72.USD","01801","LU0456827905.SGD","02596","01276","LU0320764599.SGD","01177","HK0000306685.HKD","06160","02269","09926","03692","LU2399975544.HKD","02273","06821","LU0181495838.USD","00013","06078","06996","LU0140636845.USD","LU1242518857.USD","LU3063872942.SGD","02268","01951","02096","03759","09966","LU1226287875.USD","01952","LU1688375341.USD","LU0502904849.HKD","02162","LU0051755006.USD","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257792","title":"港股异动 | 创新药概念多数走高 行业BD交易延续高景气 政策支持与商业化盈利兑现逻辑不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257792","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642257792?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:50","pubTimestamp":1781247029,"startTime":"0","endTime":"0","summary":"消息面上，今年一季度，中国创新药对外授权交易总额突破600亿美元，显示出海已从“偶发大单”升级为可持续的产业能力；另一方面，ASCO 2026中国研究入选数量和学术层级也在继续提升。近期多个创新药数据读出，重要BD陆续公告，事件性催化不断；中国创新药全球竞争力持续加强，政策支持与商业化盈利兑现的产业逻辑不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","BK1583","06990","BK1161","LU2328871848.SGD","BK1574","LU0359202008.SGD","09995","06978","LU2543165471.USD","BK4585","LU1969619763.USD","BK4588","LU0359201612.USD","09969","159992","LU1023057109.AUD","LU0359201885.HKD","VXUS","BK1191","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642118285","title":"2026 EULAR︱恒瑞医药IFNAR1/TACI抗体融合蛋白SHR-2173治疗系统性红斑狼疮I期研究结果精彩亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2642118285","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642118285?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:12","pubTimestamp":1781172720,"startTime":"0","endTime":"0","summary":"2026年欧洲抗风湿病联盟年会已于当地时间6月3日至6日在英国伦敦隆重召开。期间，恒瑞医药自主研发的IFNAR1/TACI抗体融合蛋白SHR-2173用于系统性红斑狼疮的一项多中心、开放标签、多剂量递增I期临床研究成果精彩亮相1。目前，针对上述任一通路的单靶点治疗均难以实现整体病情的有效控制。各组均无导致试验终止的TEAE。本研究的初步临床证据为SHR-2173的持续开发提供了重要依据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-06-11/doc-iniaztwk5483464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU0359202008.SGD","LU1146622755.USD","LU2097828805.USD","LU1580142542.USD","LU2097828557.USD","LU1997245094.SGD","LU1328615791.USD","LU0359201885.HKD","600276","LU2580892789.USD","LU0405327494.USD","LU2488822045.USD","BK0028","LU2097828474.EUR","LU1781817850.SGD","BK0183","BK0188","BK0196","LU0359201612.USD","LU1064131003.USD","LU1997245177.USD","BK0060","LU1969619763.USD","LU2328871848.SGD","LU1820825898.SGD","LU2289578879.USD","LU2495084118.USD","LU1997244956.HKD","BK0012","LU1023057109.AUD","LU2543165471.USD","01276","BK1191","LU1255011170.USD","TACI","LU2097828631.EUR","LU2097828714.EUR","LU0405327148.USD","LU1655091616.SGD","LU1064130708.USD","LU2580892862.HKD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165673185","title":"恒瑞医药回购15万股股份，总额约703.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165673185","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165673185?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:26","pubTimestamp":1781166381,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年6月11日公布翌日披露报表，宣布回购A股股份用于A股员工持股计划。根据公告，此次公司共回购15万股A股，占回购前公司已发行股本的约0.0024%。本次回购于上海证券交易所进行，每股回购价区间为人民币46.85元至46.91元，合计支付约人民币703.35万元。公司表示，所有回购事项已获得董事会正式授权，并遵守香港联交所证券上市规则及相关法律法规。公司方面亦表示，所购回股份暂无进行注销安排，将持作库存股份处理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购15万股股份，总额约703.35万元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642470626","title":"恒瑞医药三款新药获批临床，创新研发再添新进展｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2642470626","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642470626?lang=zh_cn&edition=full","pubTime":"2026-06-11 09:31","pubTimestamp":1781141460,"startTime":"0","endTime":"0","summary":"截至6月10日收盘，市场全天震荡调整，沪深两市成交额2.62万亿元。医药ETF（512120）上涨1.53%，港股通生物科技ETF（159102）上涨1.40%。相关个股中，恒瑞医药上涨1.36%、药明康德上涨3.81%、片仔癀上涨0.46%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606113767626750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606113767626750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1146622755.USD","BK0060","LU1997245177.USD","600276","LU1255011170.USD","LU2495084118.USD","LU0359201612.USD","LU1023057109.AUD","LU1328615791.USD","LU1997245094.SGD","LU0405327494.USD","LU0359201885.HKD","LU1064130708.USD","BK0012","BK0188","BK1161","BK1191","LU2097828557.USD","LU2328871848.SGD","LU2543165471.USD","09939","LU0359202008.SGD","LU2148510915.USD","LU2580892862.HKD","BK0183","159938","BK0239","BK0028","LU2488822045.USD","LU2097828805.USD","BK1515","LU2097828714.EUR","LU2580892789.USD","LU1655091616.SGD","BK0196","LU2289578879.USD","01276","LU0405327148.USD","LU1580142542.USD","LU1064131003.USD","LU2097828631.EUR","LU1997244956.HKD","LU1820825898.SGD","LU1781817850.SGD","LU2097828474.EUR","BK1574","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116372725","title":"恒瑞医药回购1万股A股股份，总额约46.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116372725","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116372725?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:31","pubTimestamp":1781083862,"startTime":"0","endTime":"0","summary":"恒瑞医药（股票代码：01276）于2026年6月10日发布公告，披露公司于上海证券交易所实施了A股回购，主要用于A股员工持股计划。\n本次回购股份数量为10,000股，占回购前公司已发行股本的约0.0002%。购回价格区间为每股人民币46.02元至46.06元，合计支付约人民币46.04万元。回购完成后，公司已发行股本总数约为6,379,002,274股，库藏股数量增至约8,040,450股。\n公司在公告中确认，其已遵守上市规则及相关法律法规的规定。公告由公司联席公司秘书刘笑含签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购1万股A股股份，总额约46.04万元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642442317","title":"恒瑞医药(01276)6月10日斥资46.04万元回购1万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642442317","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642442317?lang=zh_cn&edition=full","pubTime":"2026-06-10 17:29","pubTimestamp":1781083796,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月10日，该公司斥资46.04万元回购1万股A股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LU2097828557.USD","BK0028","LU1655091616.SGD","LU1781817850.SGD","LU0405327148.USD","BK0060","LU1820825898.SGD","LU2148510915.USD","BK0239","LU1969619763.USD","LU0359201612.USD","LU1997244956.HKD","LU1328615791.USD","BK0183","399300","BK1191","LU0359201885.HKD","LU1255011170.USD","600276","LU1997245094.SGD","LU1580142542.USD","LU2097828805.USD","LU2543165471.USD","LU1997245177.USD","LU2495084118.USD","LU0405327494.USD","LU2580892862.HKD","159982","LU1064130708.USD","BK0196","LU0359202008.SGD","LU2097828474.EUR","LU2289578879.USD","LU2097828714.EUR","LU2488822045.USD","BK0012","LU2580892789.USD","LU1146622755.USD","LU1064131003.USD","01276","LU2097828631.EUR","LU1023057109.AUD","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642679744","title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642679744","media":"证券日报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642679744?lang=zh_cn&edition=full","pubTime":"2026-06-09 19:54","pubTimestamp":1781006040,"startTime":"0","endTime":"0","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765312960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642466820","title":"恒瑞医药及子公司三款药物获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2642466820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642466820?lang=zh_cn&edition=full","pubTime":"2026-06-09 17:25","pubTimestamp":1780997100,"startTime":"0","endTime":"0","summary":"6月9日，恒瑞医药（600276/01276）发布公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606093765192426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327148.USD","LU1655091616.SGD","LU1969619763.USD","01276","LU1820825898.SGD","LU2097828714.EUR","LU0359201612.USD","BK0188","LU0359201885.HKD","LU0405327494.USD","LU1064131003.USD","BK0196","LU1328615791.USD","LU1997245094.SGD","LU2097828474.EUR","LU2495084118.USD","BK0060","BK0183","LU1997244956.HKD","LU2580892862.HKD","BK0239","LU2097828805.USD","LU1580142542.USD","LU2543165471.USD","LU2580892789.USD","LU2488822045.USD","600276","LU0359202008.SGD","LU1023057109.AUD","BK1191","LU1146622755.USD","BK0012","LU1781817850.SGD","LU2097828631.EUR","LU2328871848.SGD","LU2097828557.USD","BK0028","LU2289578879.USD","LU1997245177.USD","LU1064130708.USD","LU1255011170.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113265914","title":"恒瑞医药回购7万股股份，总额约319.36万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113265914","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113265914?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:51","pubTimestamp":1780995107,"startTime":"0","endTime":"0","summary":"恒瑞医药（01276）于2026年6月9日发布翌日披露报表，公司当日通过上海证券交易所回购用于A股员工持股计划的A股股份7万股，占回购前公司已发行股本约0.0011%。本次回购价格区间为每股人民币45.30元至45.82元，合计耗资约人民币319.36万元。\n公告显示，截至本次回购完成后，公司已发行股本总数仍为6,379,002,274股，库存股数量由7,960,450股增至8,030,450股。公司确认已遵守香港联交所证券上市规则及相关法律法规的各项规定。\n本公告由联席公司秘书刘笑含签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购7万股股份，总额约319.36万元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642146314","title":"恒瑞医药(01276)6月9日斥资319.36万元回购7万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642146314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642146314?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:49","pubTimestamp":1780994962,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月9日，该公司斥资人民币319.36万元回购7万股A股股份，每股回购价人民币45.3-45.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","BK0012","LU0359201612.USD","BK0188","LU1997245177.USD","399300","LU2328871848.SGD","LU0359201885.HKD","BK0183","01276","LU2097828474.EUR","LU2097828631.EUR","BK0028","LU2495084118.USD","LU1146622755.USD","LU1023057109.AUD","LU1997244956.HKD","LU1064130708.USD","LU2580892862.HKD","BK0060","LU2580892789.USD","LU1781817850.SGD","LU2097828714.EUR","LU1655091616.SGD","LU1580142542.USD","BK0196","BK1191","LU0405327148.USD","LU1997245094.SGD","LU2148510915.USD","LU2488822045.USD","LU0405327494.USD","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","LU1969619763.USD","LU2543165471.USD","600276","LU2097828805.USD","LU1255011170.USD","LU1820825898.SGD","159982","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144122879","title":"恒瑞医药回购44.4万股股份，耗资约2,042.57万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144122879","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144122879?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:22","pubTimestamp":1780906940,"startTime":"0","endTime":"0","summary":"恒瑞医药于2026年6月8日发布翌日披露报表，披露了当日在上海证券交易所回购部分A股股份的情况。本次公司合计回购A股股份444,000股，占回购前公司已发行股本的约0.007%。回购价格区间为每股人民币45.66元至46.31元，合计支付总金额人民币20,425,716元，即约2,042.57万元。公司表示，此次回购股份将被持作库存股份，用于A股员工持股计划。本次回购完成后，公司已发行股本减少至6,371,041,824股，库存股份数增至7,960,450股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购44.4万股股份，耗资约2,042.57万元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641029491","title":"恒瑞医药(01276)6月8日斥资2042.57万元回购44.4万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641029491","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641029491?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:21","pubTimestamp":1780906880,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月8日，该公司斥资2042.57万元回购44.4万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","LU2580892789.USD","LU1146622755.USD","LU2097828631.EUR","LU1023057109.AUD","LU0359201885.HKD","LU1997245177.USD","159982","LU0405327494.USD","BK0239","LU2097828714.EUR","399300","LU2289578879.USD","01276","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","LU1255011170.USD","LU2097828805.USD","LU1997244956.HKD","LU1820825898.SGD","BK0183","LU1997245094.SGD","BK0196","BK0188","LU2328871848.SGD","LU2580892862.HKD","LU2097828557.USD","LU1064130708.USD","LU1781817850.SGD","LU1580142542.USD","BK0060","BK0028","LU0359201612.USD","LU1969619763.USD","LU2495084118.USD","LU1655091616.SGD","LU1328615791.USD","LU2097828474.EUR","LU0359202008.SGD","LU2543165471.USD","BK1191","LU0405327148.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641599102","title":"智通AH统计|6月8日","url":"https://stock-news.laohu8.com/highlight/detail?id=2641599102","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641599102?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:15","pubTimestamp":1780906506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止6月8日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为743.75%、340.67%、301.45%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-30.32%、-15.46%、-5.19%。其中东北电气、晨鸣纸业、上海石油化工股份的偏离值位居前三，分别为146.57%、50.41%、48.52%；另外，浙江世宝、绿色动力环保、南华期货股份的偏离值位居后三，分别为-24.18%、-15.90%、-13.40%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02359","01330","EWH","BK1514","00317","BK1110","06031","00300","02603","03143","00916","01276","LU1675838814.USD","02727","02691","LU1794554557.SGD","03678","01812","02208","00991","SG9999001093.SGD","02338","LU1688375341.USD","00042","03750","00699","399300","01349","LU0890818403.SGD","01108","00568","BK1544","02218","02039","159982","LU0823426480.USD","03968","03986","03200","LU1366334651.USD","01057","02899","00338","00719","06166","LU2097828474.EUR","03328","01033","00187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199380652","title":"恒瑞医药回购200,000股股份，总额约945.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1199380652","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199380652?lang=zh_cn&edition=full","pubTime":"2026-06-05 16:37","pubTimestamp":1780648644,"startTime":"0","endTime":"0","summary":"恒瑞医药（股票代码：01276）于2026年6月5日发布公告，披露公司于2026年6月4日在上海证券交易所回购普通股股份200,000股，用于A股员工持股计划。本次回购股份约占该事件前公司已发行股本（不含库藏股）的0.0031%。\n据公告披露，上述回购价格最高为每股人民币47.45元，最低为每股人民币47.05元，合计支付约945.37万元人民币。回购完成后，公司已发行股本（不含库藏股）变更为6,371,485,824股，库藏股数量增至7,516,450股。\n公司同时确认，该回购事项已获公司董事会正式授权，并遵守了所有适用的上市规则与相关法律法规。公告由联席公司秘书刘笑含签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购200,000股股份，总额约945.37万元","news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641619989","title":"港股异动 | 恒瑞医药(01276)涨超5% “双艾”组合联合TACE治疗不可切除肝癌Ⅲ期研究结果亮相ASCO年会","url":"https://stock-news.laohu8.com/highlight/detail?id=2641619989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641619989?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:55","pubTimestamp":1780624500,"startTime":"0","endTime":"0","summary":"消息面上，据恒瑞医药官微消息，近日，在ASCO 2026年会上，公司创新药“双艾”组合联合经动脉化疗栓塞术对比单纯TACE治疗不可切除肝细胞癌的全国多中心、随机对照、III期研究亮相口头报告环节。该研究为这一“TACE联合靶免”治疗策略在uHCC中的应用提供了有力的循证支持。基于该研究，“双艾”组合联合TACE治疗不可切除的肝细胞癌的上市许可申请已于2026年年初获国家药监局受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600276","LU2328871848.SGD","LU1781817850.SGD","BK0239","LU2097828714.EUR","BK0028","BK0060","LU0359202008.SGD","LU2580892789.USD","LU2097828557.USD","BK0196","LU1023057109.AUD","LU1997245094.SGD","LU1064130708.USD","LU2097828805.USD","LU0405327494.USD","LU2580892862.HKD","LU2148510915.USD","LU1820825898.SGD","VXUS","LU0359201612.USD","BK0183","LU2543165471.USD","TACE","LU2097828631.EUR","LU1255011170.USD","01276","BK4588","LU1064131003.USD","LU1580142542.USD","LU0359201885.HKD","BK0012","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1997244956.HKD","LU1969619763.USD","LU1997245177.USD","LU2097828474.EUR","BK1191","LU2289578879.USD","LU2495084118.USD","BK0188","LU1655091616.SGD","BK4585","LU1146622755.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134438654","title":"异动解读｜恒瑞医药盘中上涨3.28%，ASCO年会强势亮相叠加回购提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1134438654","media":"行情直击","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134438654?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:50","pubTimestamp":1780624228,"startTime":"0","endTime":"0","summary":"6月5日，恒瑞医药盘中上涨3.28%，报55.8港元，成交额9290.42万港元。消息面上，多重利好共振推动股价反弹。此前股价因中美政策传闻误读式恐慌自高点回撤约34%，当前基本面改善信号持续释放，市场情绪有所修复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117441306","title":"恒瑞医药回购42万股股份，涉资约1,982.37万人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1117441306","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117441306?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:21","pubTimestamp":1780564878,"startTime":"0","endTime":"0","summary":"恒瑞医药（股票代码：01276）于2026年6月4日披露翌日报表，公司当日回购A股用于A股员工持股计划，合计回购42万股，约占回购前现有已发行股本的0.0066%。回购价格区间为每股人民币46.70元至47.70元，回购总金额为约人民币1,982.37万元。\n本次回购完成后，恒瑞医药已发行股份（不包括库存股份）总数变更为6,371,685,824股，库存股份数量增加至7,316,450股。公司确认本次股份回购已获得董事会正式授权批准，并符合相关上市规则与适用法律法规。\n本公告由联席公司秘书刘笑含签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"恒瑞医药回购42万股股份，涉资约1,982.37万人民币","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640155910","title":"恒瑞医药(01276)6月4日斥资1982.37万元回购42万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2640155910","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640155910?lang=zh_cn&edition=full","pubTime":"2026-06-04 17:18","pubTimestamp":1780564719,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年6月4日，该公司斥资人民币1982.37万元回购42万股A股股份，每股回购价人民币46.7-47.7元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","LU1997244956.HKD","LU2543165471.USD","BK0060","LU2097828805.USD","LU1820825898.SGD","BK0012","LU2097828474.EUR","LU2289578879.USD","LU2488822045.USD","BK0028","01276","LU1580142542.USD","LU1655091616.SGD","LU2328871848.SGD","LU2580892862.HKD","LU1997245094.SGD","LU0359201612.USD","600276","LU2097828557.USD","LU1997245177.USD","399300","LU1023057109.AUD","LU1969619763.USD","LU1064130708.USD","LU2097828631.EUR","LU1781817850.SGD","159982","BK1191","LU0359201885.HKD","LU1146622755.USD","LU1255011170.USD","LU0405327494.USD","BK0183","BK0239","LU2148510915.USD","LU0405327148.USD","LU1328615791.USD","BK0188","LU2097828714.EUR","LU2580892789.USD","LU0359202008.SGD","LU1064131003.USD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":-0.1779},{"period":"3month","weight":-0.1719},{"period":"6month","weight":-0.2328},{"period":"1year","weight":-0.0884},{"period":"ytd","weight":-0.2388}],"compareEarnings":[{"period":"1week","weight":-0.0029},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.0588},{"period":"6month","weight":-0.0394},{"period":"1year","weight":0.018},{"period":"ytd","weight":-0.0443}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}